Heart Failure: Evolving Treatment Choices and New Guidance (webcourse)

Format: Webcourse

Credit(s): 1.00 (60 min)

Release Date: Oct 24, 2022

Expiration Date: Oct 24, 2023

Credit Type(s):

Physicians – AMA PRA Category 1 Credit(s) ™
Physicians/ABIM MOC – ABIM MOC Point(s)

PROGRAM OVERVIEW

The number of Americans with HF is increasing. Despite the many agents approved to manage HF, the prognosis has only improved somewhat, with a 5-year mortality rate after initial hospitalization of 42.3%. Guidelines are frequently updated, with the most recent ACC consensus on optimizing treatment published in 2022. Some agents to treat HFrEF are relatively new and several agents are in late-stage development. For patients with HFpEF there are currently no approved therapies although there are agents in phase 3 clinical trials.

Heart Failure: Evolving Treatment Choices and New Guidance will address the rapidly shifting HF management paradigm, providing information about the most recent evidence-based recommendations for managing HFrEF, newer approved agents, and those agents for which approval is anticipated soon, as well as agents in late-stage investigation for the management of HFpEF.